𝗦𝘆𝘀𝘁𝗲𝗺𝗮𝘁𝗶𝗰 𝗟𝗶𝘁𝗲𝗿𝗮𝘁𝘂𝗿𝗲 𝗥𝗲𝘃𝗶𝗲𝘄𝘀 (𝗦𝗟𝗥𝘀): 𝗙𝗿𝗼𝗺 𝗣𝗿𝗼𝘁𝗼𝗰𝗼𝗹 𝘁𝗼 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗔𝗰𝗰𝗲𝘀𝘀

🔬

In modern pharma, SLRs are not just about gathering evidence—they are about building a defensible, transparent, and decision-grade foundation that shapes how therapies are developed, evaluated, and ultimately accessed by patients.

🧭 Step-by-step: How a high-quality SLR is conducted

1️⃣ 📌 Define the research question (PICOS framework)
Population, Intervention, Comparator, Outcomes, Study design—this ensures clarity, relevance, and alignment with downstream use (e.g., HTA, NMA).

2️⃣ 📝 Develop and register the protocol
Pre-specifying methods (often aligned with PRISMA-P / PROSPERO) minimizes bias and enhances reproducibility.

3️⃣ 🔎 Design comprehensive search strategies
Structured searches across databases (e.g., MEDLINE, Embase, Cochrane), plus grey literature, conference abstracts, and trial registries.

4️⃣ 📂 Study screening & selection
Dual-reviewer screening (title/abstract → full text) with predefined inclusion/exclusion criteria to ensure consistency and reduce selection bias.

5️⃣ 🧪 Data extraction
Standardized templates capture study characteristics, endpoints, and results—ensuring completeness and traceability.

6️⃣ ⚖️ Quality assessment / Risk of Bias
Using validated tools (e.g., Cochrane RoB 2.0, ROBINS-I) to critically appraise internal validity.

7️⃣ 📊 Evidence synthesis
Qualitative synthesis for heterogeneous data
Quantitative approaches (ITCs, NMAs) for comparative effectiveness

8️⃣ 📑 Reporting (PRISMA-compliant)
Transparent documentation of methodology, study flow, and findings—critical for regulatory and HTA acceptance.

🔗 Why this rigor matters in drug development & access:

🧪 Clinical strategy: Identifies evidence gaps, refines endpoints, and strengthens trial positioning
🏛️ Regulatory alignment: Provides structured evidence packages supporting submissions
📈 HTA & payer decisions: Enables robust comparative effectiveness and value demonstration
🚀 Faster access: Reduces uncertainty → accelerates time to reimbursement and patient uptake

💡 What’s next?
With growing data volume, living SLRs and AI-assisted workflows are transforming timelines—while maintaining methodological rigor.

👉 In a landscape where evidence drives access, the quality of your SLR can directly influence how—and how fast—patients benefit from innovation.

Comments

Curated Compendium of Drug Discovery

Drug discovery is a multidisciplinary process that integrates biology, chemistry, pharmacology , and cutting-edge technologies to identify and develop new therapeutic agents. From target identification to lead optimization and clinical evaluation, each stage requires precision, innovation, and collaboration. A curated list of drug discovery resources provides researchers, students, and professionals with a structured pathway to explore advancements, tools, and strategies that shape modern therapeutics. This compilation serves as a gateway to understanding the evolution of drug discovery, recent breakthroughs, and future directions, fostering knowledge-sharing and accelerating translational research. Databases and Chemical Libraries General Compound Libraries DrugBank - Comprehensive data on approved and investigational drugs. ZINC - Free compounds for screening. ChemSpider - Chemical structures and data. DrugSpaceX - Chemical and biological spaces. Mcule ...

Understanding NMR Spectroscopy and Chemical Shift Ranges for Functional Groups

Nuclear Magnetic Resonance ( NMR ) spectroscopy is one of the most powerful analytical tools in pharmaceutical chemistry. It helps chemists determine the structure, purity, and chemical environment of molecules by analyzing the behavior of nuclei (commonly ¹H or ¹³C ) when exposed to a strong magnetic field. In proton NMR ( ¹H-NMR ), the chemical shift (δ, in ppm) provides information about the type of hydrogen atoms present in a compound and their surrounding electronic environment. Depending on nearby atoms and functional groups, signals appear in specific regions of the spectrum — often referred to as upfield (shielded, lower δ values) or downfield (deshielded, higher δ values). The image above summarizes the characteristic δ ranges for different functional groups in ¹H-NMR. Let us break it down systematically: 1. Downfield Region (δ 12 – 6 ppm) Hydrogens in this region are strongly deshielded due to electronegative atoms or π-bond systems. Carboxylic Acids (–COOH) : δ 1...

Pushing the boundaries of computational drug discovery at Isomorphic Labs

The Isomorphic Labs Drug Design Engine (IsoDDE) has unlocked a new frontier in in-silico drug design, representing a significant evolution beyond AlphaFold 3. What IsoDDE delivers: 🔹 Massive accuracy leap on unconstrained structure prediction The engine more than doubles AlphaFold 3's accuracy on extremely challenging protein-ligand prediction tasks — including systems far outside the training distribution. 🔹 Best-in-class binding affinity prediction IsoDDE predicts how strongly small molecules bind to targets with accuracy that exceeds gold-standard physics-based methods, at a fraction of the computational cost and time. 🔹 Blind identification of novel binding pockets Even without existing structural data, the engine reveals previously unseen binding sites — just from an amino acid sequence — enabling drug designers to explore entirely new chemical action spaces. 🔹 Expanded support for complex biologics Beyond small molecules, the engine boosts prediction fidelity for...

NEOPHARMA NUTSHELL COMMUNITY

Search This Blog